Samsung Bioepis Initiates P-Ill Study of SB16 Proposed Biosimilar to Prolia (denosumab)
Shots:
- The P-lll study will assess the efficacy- safety- pharmacokinetics PK/PD- and immunogenicity of SB16 vs Prolia in 432 female volunteers for postmenopausal osteoporosis
- The company has initiated the P-I study to compare the PK/PD- safety- tolerability- and immunogenicity b/w SB16 and Prolia in healthy volunteers in Oct’2020
- Samsung Bioepis has three biosimilar candidates – SB12 (eculizumab)- SB15 (aflibercept)- and SB16 (denosumab) in P-III development
Ref: Samsung Bioepis | Image: Samsung Bioepis
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com